var data={"title":"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/contributors\" class=\"contributor contributor_credentials\">Wendy Y Chen, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/contributors\" class=\"contributor contributor_credentials\">Daniel F Hayes, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For women at high risk for breast cancer, endocrine therapy can reduce the risk of invasive <span class=\"nowrap\">and/or</span> in situ breast cancers. This topic will discuss the use of endocrine therapy in women at increased risk for breast cancer. Screening for breast cancer, surgical approaches to prevent breast cancer among high-risk women with a hereditary cancer syndrome, and the risk factors for the development of breast cancer are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=screening-for-breast-cancer-strategies-and-recommendations\" class=\"medical medical_review\">&quot;Screening for breast cancer: Strategies and recommendations&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-hereditary-breast-and-ovarian-cancer-syndromes\" class=\"medical medical_review\">&quot;Overview of hereditary breast and ovarian cancer syndromes&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=factors-that-modify-breast-cancer-risk-in-women\" class=\"medical medical_review\">&quot;Factors that modify breast cancer risk in women&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-patients-at-high-risk-for-breast-and-ovarian-cancer#H373708411\" class=\"medical medical_review\">&quot;Management of patients at high risk for breast and ovarian cancer&quot;, section on 'Risk-reducing surgery'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H9621357\"><span class=\"h1\">PATIENT SELECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For women who are at an increased risk for breast cancer, we agree with guidelines from the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the United States Preventive Services Task Force (USPSTF) and discuss the role of endocrine therapy (<a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> or <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a>) for breast cancer prevention [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Selection criteria used in the breast cancer prevention trials varied somewhat [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/4-7\" class=\"abstract_t\">4-7</a>]. Our criteria are the same as those adopted by ASCO and include [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/8\" class=\"abstract_t\">8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age of 35 years or older with a life expectancy of at least 10 years and one of the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A history of lobular carcinoma in situ (LCIS). (See <a href=\"topic.htm?path=atypia-and-lobular-carcinoma-in-situ-high-risk-lesions-of-the-breast\" class=\"medical medical_review\">&quot;Atypia and lobular carcinoma in situ: High-risk lesions of the breast&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A &ge;1.7 percent five-year risk for breast cancer as determined by the modified Gail model. (See <a href=\"topic.htm?path=screening-for-breast-cancer-strategies-and-recommendations#H2819905921\" class=\"medical medical_review\">&quot;Screening for breast cancer: Strategies and recommendations&quot;, section on 'Gail model'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atypical hyperplasia</p><p/><p>Although mastectomy is an option to prevent breast cancer, it is only recommended in women at high risk due to germline mutations of <em>BRCA1</em> or <em>BRCA2 </em>or other genes that may carry a 50 percent or higher lifetime risk for developing breast cancer. For those with <em>BRCA1</em> and <em>BRCA2</em> mutations who do not undergo mastectomy, limited retrospective data suggest a benefit with <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=management-of-patients-at-high-risk-for-breast-and-ovarian-cancer\" class=\"medical medical_review\">&quot;Management of patients at high risk for breast and ovarian cancer&quot;</a>.)</p><p>There are no data on the use of either the selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) for breast cancer prevention in men. Given the low overall incidence of breast cancer in men and the lack of data to inform the benefits versus risks of chemoprevention, we recommend against the use of these agents in men. </p><p class=\"headingAnchor\" id=\"H442158384\"><span class=\"h1\">SELECTIVE ESTROGEN RECEPTOR MODULATORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> and <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> are reasonable options for women at an increased risk of breast cancer. When administered for prevention in the trials below, treatment was generally administered for five years. Although two trials in the adjuvant treatment setting for breast cancer show that 10 years of tamoxifen improved outcomes compared with five years, the benefits and risks of a more prolonged course in the setting of prevention has not been defined. Therefore, we do not prescribe selective estrogen receptor modulators (SERMs) for more than five years in the context of breast cancer prevention. (See <a href=\"topic.htm?path=adjuvant-endocrine-therapy-for-non-metastatic-hormone-receptor-positive-breast-cancer#H38114838\" class=\"medical medical_review\">&quot;Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer&quot;, section on 'Duration of endocrine treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H31421388\"><span class=\"h2\">Tamoxifen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the normal breast and in breast cancer, <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> blocks the effects of endogenous estrogen. By contrast, it produces estrogen-like effects in the uterus, bone, liver, and coagulation system. In addition to being a treatment option for hormone receptor-positive breast cancer, it is approved in the United States for use as prevention in women considered at high risk for breast cancer. The decision to use tamoxifen should take into consideration values and preferences for treatment, which are discussed below [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/10-12\" class=\"abstract_t\">10-12</a>]. (See <a href=\"topic.htm?path=mechanisms-of-action-of-selective-estrogen-receptor-modulators-and-down-regulators\" class=\"medical medical_review\">&quot;Mechanisms of action of selective estrogen receptor modulators and down-regulators&quot;</a> and <a href=\"topic.htm?path=managing-the-side-effects-of-tamoxifen\" class=\"medical medical_review\">&quot;Managing the side effects of tamoxifen&quot;</a>.)</p><p>The benefits of <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> were summarized using data from four trials in the 2013 US Preventive Services Task Force (USPSTF) meta-analysis [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/13\" class=\"abstract_t\">13</a>]. Compared with placebo, tamoxifen resulted in:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A reduction in the risk of invasive breast cancer (seven cases in 1000 women over five years, risk ratio [RR] 0.70, 95% CI 0.59-0.82). This was primarily seen as a reduction in the risk of estrogen receptor-positive breast cancer. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A significant reduction in the incidence of non-vertebral fractures (three cases in 1000 women, RR 0.66, 95% CI 0.45-0.98).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No difference in breast cancer-specific or all-cause mortality.</p><p/><p>In addition to these results, long-term follow-up of the International Breast Cancer Intervention Study I (IBIS-1) showed that <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> resulted in long-term reduction in the risk of hormone receptor-positive breast cancer. In IBIS-1, over 7000 women (aged 30 to 75 years at study entry) were randomly assigned to five years of tamoxifen or placebo. With median follow-up of 16 years [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/14\" class=\"abstract_t\">14</a>], tamoxifen reduced the risk of invasive breast cancer between years 0 and 10 (hazard ratio [HR] 0.72, 95% CI 0.59-0.88) and after 10 years (HR 0.69, 95% CI 0.53-0.91), compared with placebo. As expected, this risk reduction was only for hormone receptor-positive breast cancer (HR 0.66, 95% CI 0.54-0.81), but not for hormone receptor-negative breast cancer (HR 1.05, 95% CI 0.71-1.57).</p><p>While the benefits of <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> are now well-established, treatment is also associated with several risks. These include [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/13\" class=\"abstract_t\">13</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An increased incidence of thromboembolic events (four cases in 1000 women, RR 1.93, 95% CI 1.41-2.64). For example, the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial showed a trend towards higher stroke rates (1.75 versus 1.23 cases per 1000 women, RR 1.42, 95% CI 0.97-2.08) and pulmonary embolism (0.69 versus 0.32 cases per 1000 women, RR 2.15, 95% CI 1.08-4.51) [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/4\" class=\"abstract_t\">4</a>]. Of note, the risk of tamoxifen-related thromboembolic events does not appear to be related to the presence of mutations that promote blood coagulation, including mutations in factor V Leiden or in the prothrombin gene [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=factor-v-leiden-and-activated-protein-c-resistance\" class=\"medical medical_review\">&quot;Factor V Leiden and activated protein C resistance&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An increased incidence of endometrial cancer (four cases in 1000 women, RR 2.13, 95% CI 1.36-3.32). In IBIS-1, the risk of endometrial cancer was elevated in the first five years of treatment (odds ratio [OR] 3.76, 95% CI 1.20-15.56), but not after five years (OR 0.64 with 5 to 10-year follow-up, 95% CI 0.21-1.80) [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p>Risks of thromboembolic events and endometrial cancer with <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> are age-related, increasing with advancing age.</p><p>While the risks of <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> are increased compared with placebo, it is important to note that the overall incidence of adverse events appears to be small. In addition, two studies have addressed quality of life (QOL) issues in women enrolled in placebo-controlled trials of tamoxifen for the prevention of breast cancer [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Compared with women receiving placebo, tamoxifen use was not associated with any significant differences in depression, anxiety, major psychosocial outcomes, or overall QOL.</p><p class=\"headingAnchor\" id=\"H31421397\"><span class=\"h2\">Raloxifene</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">Raloxifene</a> is another option for women who may be at an increased risk for tamoxifen-related complications. Raloxifene has estrogenic effects on bone and lipids, but estrogen antagonist effects on the breast and uterus [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/18\" class=\"abstract_t\">18</a>]. In addition to its approval as an agent for breast cancer prevention, it is approved for the treatment of postmenopausal osteoporosis. </p><p>The benefits and risks of <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> were also summarized using data from two trials in the 2013 USPSTF meta-analysis [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/13\" class=\"abstract_t\">13</a>]. Compared with placebo, raloxifene resulted in:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A reduction in the risk of invasive breast cancer (nine cases in 1000 women, RR 0.44, 95% CI 0.27-0.71). As with <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>, the risk was reduced primarily for the development of estrogen receptor-positive breast cancers.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A reduction in the incidence of vertebral fractures (seven cases in 1000 women, RR 0.61, 95% CI 1.41-2.64).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No increased incidence of endometrial cancer.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No difference in breast cancer-specific or all-cause mortality.</p><p/><p class=\"headingAnchor\" id=\"H2423700\"><span class=\"h2\">Choice of tamoxifen versus raloxifene</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> and <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> for chemoprevention was confirmed in a 2013 meta-analysis for the USPSTF that included seven randomized trials (predominantly involving postmenopausal women) [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/2\" class=\"abstract_t\">2</a>]. The follow-up varied for each agent, but ranged from 7 to 13 years for the studies on tamoxifen and four to eight years for the studies on raloxifene [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/2,13\" class=\"abstract_t\">2,13</a>]. The primary results were as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The administration of <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> or <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> for five years reduced the incidence of breast cancer by 7 to 9 cases per 1000 women. This risk reduction is greatest among women with an estimated five-year risk &ge;3 percent based on model estimates (eg, Gail model). However, in one of these trials (the Study of Tamoxifen And Raloxifene), which directly compared tamoxifen with raloxifene, tamoxifen was slightly more effective at preventing invasive breast cancer [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"#H9621357\" class=\"local\">'Patient selection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment with either SERM did not significantly reduce the risk for non-invasive breast cancer or mortality. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although both <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> and <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> increased the risk of thromboembolic events compared with placebo (by approximately 4 to 7 events per 1000 women over five years), the risk is greater with tamoxifen (by approximately 4 cases per 1000 women). In addition, tamoxifen resulted in greater risks of cataracts and endometrial cancer (particularly in women 50 years or older).</p><p/><p>These data show that both SERMs are effective agents as chemoprevention among women at higher risk of breast cancer. Decisions about whether to start a SERM and which agent are discussed below. (See <a href=\"#H31421174\" class=\"local\">'Treatment approach'</a> below.) </p><p class=\"headingAnchor\" id=\"H442158426\"><span class=\"h1\">AROMATASE INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The aromatase inhibitors (AIs) suppress plasma estrogen levels by inhibition of the enzyme aromatase, which is responsible for the peripheral conversion of androgens to estrogens. AIs are standard options in the treatment of postmenopausal breast cancer. Of the AIs, only <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/20\" class=\"abstract_t\">20</a>] and <a href=\"topic.htm?path=exemestane-drug-information\" class=\"drug drug_general\">exemestane</a> [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/21\" class=\"abstract_t\">21</a>] have been evaluated for primary prevention and showed similar results. </p><p>The benefit of an AI as prevention was demonstrated in the International Breast cancer Intervention Study (IBIS-II), which enrolled approximately 4000 postmenopausal women at high risk of breast cancer and randomly assigned them to treatment with <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> or placebo for five years [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/20\" class=\"abstract_t\">20</a>]. Eligibility criteria were complex and different for different age groups, but generally high risk was defined as two or more blood relatives with breast cancer, mother or sister with breast cancer before 50 years, mother or sister with bilateral breast cancer, or high-risk benign breast disease. After a median follow-up of five years, main results were as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There was a 50 percent reduction in the number of invasive breast cancers with <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> compared with placebo (32 [2 percent] versus 64 [3 percent], respectively, hazard ratio [HR] 0.47, 95% CI 0.32-0.68). Treatment with anastrozole resulted in a similar decrease in the incidence of ductal carcinoma in situ (DCIS).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">Anastrozole</a> resulted in significantly more musculoskeletal side effects (64 versus 58 percent), hypertension (5 versus 3 percent), vaginal dryness (19 versus 16 percent,), and vasomotor symptoms (57 versus 49 percent).</p><p/><p>Overall, these data indicate that AIs are a reasonable alternative to selective estrogen receptor modulators (SERMs) for postmenopausal women, although none are approved for this indication in the United States at this time. It should also be noted that the AIs may be associated with a loss of bone density, which may be important to consider in this population.</p><p class=\"headingAnchor\" id=\"H31421174\"><span class=\"h1\">TREATMENT APPROACH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We agree with guidelines from the US Preventive Services Task Force (USPSTF) [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/2\" class=\"abstract_t\">2</a>] and the American Society of Clinical Oncology (ASCO) [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/22\" class=\"abstract_t\">22</a>], both of which support the administration of endocrine therapy for women at high risk for breast cancer. While both organizations support the use of selective estrogen receptor modulators (SERMs), only ASCO considers the use of the aromatase inhibitor (AI) <a href=\"topic.htm?path=exemestane-drug-information\" class=\"drug drug_general\">exemestane</a> as a reasonable alternative to the SERMs for postmenopausal women [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/22\" class=\"abstract_t\">22</a>]. Because the data from the International Breast cancer Intervention Study (IBIS-II) trial were published in 2014, neither organization has commented on the incorporation of <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> as a treatment option. It should be noted that none of the primary prevention trials were powered for a difference in survival. </p><p>Our general approach is based upon whether or not a woman is menopausal: </p><p class=\"headingAnchor\" id=\"H31421749\"><span class=\"h2\">Postmenopausal women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For postmenopausal women at increased risk for breast cancer, we suggest endocrine therapy for prevention with treatment administered for a total of five years. Both selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) appear to be reasonable options, although only <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> and <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> have received US Food and Drug Administration (FDA) approval for risk reduction for primary prevention. A choice among agents should be individualized based on their comparative risk profiles. For women who prefer a SERM, we suggest raloxifene if they are more concerned about uterine cancer and thromboembolic risks than their risk of breast cancer. For women who are more concerned about breast cancer prevention or have had a hysterectomy, we suggest tamoxifen. For women who desire breast cancer prevention but would rather not take a SERM for whatever reason, an AI is reasonable. Both <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> and <a href=\"topic.htm?path=exemestane-drug-information\" class=\"drug drug_general\">exemestane</a> appear to be equally effective. In general, the risk-benefit ratio for primary prevention will be more favorable for younger women, those without a uterus, and those at highest risk of developing breast cancer. </p><p>Whether an AI is a more effective chemoprevention than a SERM is unknown, since they have not been directly compared. However, an AI is a reasonable alternative to <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> or <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> for postmenopausal women at an increased risk of breast cancer.</p><p>For women who are candidates for a SERM, a risk model has attempted to estimate the benefits of <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> or <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> versus risks of life-threatening events (ie, invasive breast cancer, hip fracture, endometrial cancer, stroke, or pulmonary embolism) based on race and on whether or not they had an intact uterus [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/23\" class=\"abstract_t\">23</a>]. However, there are several limitations of this model including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <span class=\"nowrap\">risk/benefit</span> ratios are quite sensitive to the specific weights chosen for life-threatening, severe, and other events, particularly treatment-related adverse effects. For some women who may be concerned about a particular health outcome, a decision on endocrine therapy based on individualized consideration of the risks may be more appropriate. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>This model overestimates the benefit of <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> since it was published before the updated Study of <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">Tamoxifen</a> and Raloxifene (STAR) trial data were available, which showed that raloxifene was less effective than tamoxifen in terms of breast cancer prevention.</p><p/><p class=\"headingAnchor\" id=\"H2105620482\"><span class=\"h2\">Premenopausal women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For premenopausal women at high risk for breast cancer, we suggest <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> for five years rather than observation, which is consistent with the recommendations of ASCO and USPSTF [<a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/2,22\" class=\"abstract_t\">2,22</a>]. AIs are contraindicated in women with intact ovarian function. There are no data on the efficacy of <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> for breast cancer prevention among premenopausal women.</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=medications-for-the-prevention-of-breast-cancer-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Medications for the prevention of breast cancer (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A major public health focus is the prevention of breast cancer. Among women at high risk for breast cancer, endocrine therapy can reduce the risk of the development of invasive <span class=\"nowrap\">and/or</span> in situ breast cancers. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Women with an inherited germline mutation of <em>BRCA1</em> or <em>BRCA2 </em>or other genes that may carry a 50 percent or higher lifetime risk for developing breast cancer should be counseled on the role of prophylactic mastectomy. (See <a href=\"topic.htm?path=management-of-patients-at-high-risk-for-breast-and-ovarian-cancer\" class=\"medical medical_review\">&quot;Management of patients at high risk for breast and ovarian cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For women at an increased risk for developing breast cancer, we suggest endocrine therapy rather than observation (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H9621357\" class=\"local\">'Patient selection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For postmenopausal women, both selective estrogen receptor modulators (SERMs, <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> or <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a>) and aromatase inhibitors (AIs, <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> or <a href=\"topic.htm?path=exemestane-drug-information\" class=\"drug drug_general\">exemestane</a>) are reasonable options. A choice among them should be individualized. (See <a href=\"#H31421749\" class=\"local\">'Postmenopausal women'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For women who prefer a SERM, we suggest <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a> if they are more concerned about uterine cancer and thromboembolic risks than their risk of breast cancer (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). For women who are more concerned about breast cancer prevention, we suggest <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For women who desire breast cancer prevention but would rather not take a SERM for whatever reason, an AI is reasonable. Both <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a> and <a href=\"topic.htm?path=exemestane-drug-information\" class=\"drug drug_general\">exemestane</a> appear to be equally effective.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For premenopausal women at high risk of breast cancer, we suggest <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> rather than observation (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). These women are not candidates for an AI or <a href=\"topic.htm?path=raloxifene-drug-information\" class=\"drug drug_general\">raloxifene</a>. (See <a href=\"#H2105620482\" class=\"local\">'Premenopausal women'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/1\" class=\"nounderline abstract_t\">Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27:3235.</a></li><li class=\"breakAll\">Medications for Risk Reduction of Primary Breast Cancer in Women. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrpv.htm (Accessed on October 02, 2013).</li><li class=\"breakAll\">https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf (Accessed on August 03, 2017).</li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/4\" class=\"nounderline abstract_t\">Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/5\" class=\"nounderline abstract_t\">Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/6\" class=\"nounderline abstract_t\">Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99:283.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/7\" class=\"nounderline abstract_t\">Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99:727.</a></li><li class=\"breakAll\">NCCN Guidelines for Detection, Prevention, &amp; Risk Reduction: Breast Cancer Risk Reduction http://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf (Accessed on March 02, 2016).</li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/9\" class=\"nounderline abstract_t\">King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286:2251.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/10\" class=\"nounderline abstract_t\">Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005; 103:1996.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/11\" class=\"nounderline abstract_t\">Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004; 22:4951.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/12\" class=\"nounderline abstract_t\">Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8:580.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/13\" class=\"nounderline abstract_t\">Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158:604.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/14\" class=\"nounderline abstract_t\">Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16:67.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/15\" class=\"nounderline abstract_t\">Abramson N, Costantino JP, Garber JE, et al. Effect of Factor V Leiden and prothrombin G20210--&gt;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 2006; 98:904.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/16\" class=\"nounderline abstract_t\">Fallowfield L, Fleissig A, Edwards R, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001; 19:1885.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/17\" class=\"nounderline abstract_t\">Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17:2659.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/18\" class=\"nounderline abstract_t\">Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/19\" class=\"nounderline abstract_t\">Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010; 3:696.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/20\" class=\"nounderline abstract_t\">Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014; 383:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/21\" class=\"nounderline abstract_t\">Goss PE, Ingle JN, Al&eacute;s-Mart&iacute;nez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/22\" class=\"nounderline abstract_t\">Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:2942.</a></li><li><a href=\"https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention/abstract/23\" class=\"nounderline abstract_t\">Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011; 29:2327.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 756 Version 25.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H9621357\" id=\"outline-link-H9621357\">PATIENT SELECTION</a></li><li><a href=\"#H442158384\" id=\"outline-link-H442158384\">SELECTIVE ESTROGEN RECEPTOR MODULATORS</a><ul><li><a href=\"#H31421388\" id=\"outline-link-H31421388\">Tamoxifen</a></li><li><a href=\"#H31421397\" id=\"outline-link-H31421397\">Raloxifene</a></li><li><a href=\"#H2423700\" id=\"outline-link-H2423700\">Choice of tamoxifen versus raloxifene</a></li></ul></li><li><a href=\"#H442158426\" id=\"outline-link-H442158426\">AROMATASE INHIBITORS</a></li><li><a href=\"#H31421174\" id=\"outline-link-H31421174\">TREATMENT APPROACH</a><ul><li><a href=\"#H31421749\" id=\"outline-link-H31421749\">Postmenopausal women</a></li><li><a href=\"#H2105620482\" id=\"outline-link-H2105620482\">Premenopausal women</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H20\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-endocrine-therapy-for-non-metastatic-hormone-receptor-positive-breast-cancer\" class=\"medical medical_review\">Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atypia-and-lobular-carcinoma-in-situ-high-risk-lesions-of-the-breast\" class=\"medical medical_review\">Atypia and lobular carcinoma in situ: High-risk lesions of the breast</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=factor-v-leiden-and-activated-protein-c-resistance\" class=\"medical medical_review\">Factor V Leiden and activated protein C resistance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=factors-that-modify-breast-cancer-risk-in-women\" class=\"medical medical_review\">Factors that modify breast cancer risk in women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-patients-at-high-risk-for-breast-and-ovarian-cancer\" class=\"medical medical_review\">Management of patients at high risk for breast and ovarian cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=managing-the-side-effects-of-tamoxifen\" class=\"medical medical_review\">Managing the side effects of tamoxifen</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanisms-of-action-of-selective-estrogen-receptor-modulators-and-down-regulators\" class=\"medical medical_review\">Mechanisms of action of selective estrogen receptor modulators and down-regulators</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hereditary-breast-and-ovarian-cancer-syndromes\" class=\"medical medical_review\">Overview of hereditary breast and ovarian cancer syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medications-for-the-prevention-of-breast-cancer-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Medications for the prevention of breast cancer (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-for-breast-cancer-strategies-and-recommendations\" class=\"medical medical_review\">Screening for breast cancer: Strategies and recommendations</a></li></ul></div></div>","javascript":null}